CEO Peter Dolan

Bristol-Myers Squibb Co. (BMY) is making progress developing a new drug to assist the bodys immune system in its ability to find and attack cancer cells. The drug may prove especially effective fighting lung cancer. Bristol-Myers, the farthest along of at least five companies pushing ahead with this cancer-targeting approach, received U.S. approval in March 2011 on a drug that attacks...  

PRINCETON, N.J., May 29, 2012 (BUSINESS WIRE) -- Bristol-Myers Squibb Company today announced the formation of the International Immuno-Oncology Network (II-ON), a global collaboration between industry and academia that aims to further the scientific understanding of immuno-oncology. Immuno-oncology focuses on the potential of harnessing the intelligence of the body's own immune system to fight cancer...  

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Announces Global Collaboration with Leading Academic Institutions to Advance Science of Immuno-Oncology  

Bristol-Myers Squibb Company (NYSE: BMY) will take part in Sanford Bernstein's 28th Annual Strategic Decisions Conference on Thursday, May 31, 2012, in New Yo...  

CHICAGO, May 22, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include...